Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older

BACKGROUND: In Japan, over 25% of the population is elderly. As the risk of lung cancer increases with age, the number of elderly patients with lung cancer also increases. Given the challenges of an aging society, it is critical that elderly patients receive safe therapies. AIM: We assessed the safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Zentaro, Fujita, Kohei, Okamura, Misato, Ito, Takanori, Yamamoto, Yuki, Kanai, Osamu, Hashimoto, Masayuki, Nakatani, Koichi, Sawai, Satoru, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714532/
https://www.ncbi.nlm.nih.gov/pubmed/33934572
http://dx.doi.org/10.1002/cnr2.1405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714532/
https://www.ncbi.nlm.nih.gov/pubmed/33934572
http://dx.doi.org/10.1002/cnr2.1405

Ejemplares similares